White paper · Editorial summary

Measuring Outcomes in Interventional Mental Health

A working draft on why a shared, structured record of published interventional mental health research matters, and how outcomes can be compared without overclaiming.

Published July 1, 2026. Back to the research library.

Working draft. This white paper is staged so the research system can be built and verified. The final body is owned by Trevor and is not yet placed. The framing below is deliberately conservative and makes no efficacy claim.

Why a shared record matters

Interventional treatments are accumulating a real published record. That record is spread across journals, registries, and press coverage, in different scales and different reporting conventions. Read one study at a time, it is hard to see the shape of the field. Read together, with each result shown next to its source, the picture gets clearer for clinicians, researchers, and the people considering care.

This paper describes how published outcomes can be structured so they can be compared, without implying more certainty than the studies support.

What this is, and what it is not

This is a summary of published, third-party research. It is not medical advice, not a treatment recommendation, and not a statement of Arcametric outcomes. Arcametric documents and surfaces outcomes; it does not direct care and makes no efficacy claim. Nothing here describes a live network of clinics or a populated benchmark.

How outcomes are compared

Every study reports on its own terms: a sample size, a rating scale, a follow-up window, an effect size, and a rate of adverse events. Placed side by side, those fields let a reader weigh strength against durability, and see where the evidence is thin. The evidence map plots the same studies by effect size and follow-up length.

Open questions

The body of this paper, and its companion PDF, are pending. The sections above stand in for the structure so the page, the schema, and the guardrails can be verified now.

Sources

  1. Davis AK, et al. Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. JAMA Psychiatry. 2021;78(5):481-489. Link
  2. Mitchell JM, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021;27(6):1025-1033. Link

This is published, third-party research, surfaced and compared. It is not Arcametric outcomes and not a benchmark network. See the full evidence landscape or the research library.